PD-L1 combined positive score (CPS) assessment can be challenging. This webinar will explore how experienced pathologists approach these situations in real life, with a focus on PD-L1 IHC 22C3 pharmDx across the full range of tumour types.
Drawing on their experience in a specialist molecular pathology service, Dr Philippe Taniere and Dr Matt Evans will discuss practical and pragmatic approaches to CPS estimation, with a particular focus on interpretative pitfalls and managing difficult or borderline cases. They will then consider the factors that influence confidence in the reported result, including tissue selection, sample adequacy, reproducibility and concordance between PD-L1 assays.
The session will bring together manufacturer guidance, published evidence and the speakers’ practical experience to help attendees develop a structured approach to interpretation and reporting. It is aimed particularly at pathologists who understand the basic principles of CPS and want greater confidence in applying them to everyday cases.
After the webinar, attendees should be better able to:
Apply a practical, structured approach to CPS assessment, including cases close to clinically relevant cut-offs.
Recognise common interpretative pitfalls, including the distinction between tumour-associated and unrelated inflammation, heterogeneous staining and artefact.
Assess how tissue selection and sample adequacy influence confidence in a CPS result.
Interpret evidence on reproducibility and agreement between PD-L1 assays, including the limitations of applying that evidence to a particular tumour type or cut-off.
Recognise situations in which a second opinion, review of additional material or further testing may help resolve uncertainty.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
